Investor Presentation for Consolidated financial results for the quarter and year ended March 31, 2026
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences reported its highest-ever quarterly revenue in Q4FY26 at ₹6,109 Mn, up 26.4% YoY, with full-year FY26 revenue of ₹21,243 Mn growing 15.2%. The company achieved strong margin expansion with FY26 EBITDA at ₹9,896 Mn (43.4% margin, up 420 bps from 39.2%) and PAT of ₹5,918 Mn (26.0% margin, up from 23.4%). CRDMO business contributed ₹17,727 Mn (83.4% of revenue) while Specialty Ingredients added ₹3,516 Mn. Net cash position stands at ₹13,743 Mn. Exceptional items of ₹244 Mn were booked for new labour code provisions. The company is investing ₹12,000 Mn in Phase I of its new greenfield Unit IV facility at Harohalli.
Strong financial performance with meaningful margin expansion signals operational efficiency and pricing power. The healthy net cash position of ₹13,743 Mn provides flexibility for the ₹12,000 Mn Harohalli expansion while maintaining shareholder returns. Robust 30%+ EBITDA and PAT growth validates the company's growth strategy and CRDMO platform investments.